Atrion Co. (NASDAQ:ATRI – Get Free Report) announced a quarterly dividend on Tuesday, May 21st, Zacks reports. Shareholders of record on Friday, June 14th will be given a dividend of 2.20 per share by the medical instruments supplier on Friday, June 28th. This represents a $8.80 dividend on an annualized basis and a yield of 1.86%. The ex-dividend date is Friday, June 14th.
Atrion has increased its dividend by an average of 9.7% annually over the last three years and has raised its dividend annually for the last 21 consecutive years.
Atrion Price Performance
ATRI opened at $471.99 on Thursday. Atrion has a fifty-two week low of $274.98 and a fifty-two week high of $602.59. The firm’s fifty day moving average price is $427.41 and its two-hundred day moving average price is $375.64. The company has a market capitalization of $830.70 million, a P/E ratio of 44.36 and a beta of 0.62.
Analysts Set New Price Targets
Separately, StockNews.com downgraded shares of Atrion from a “hold” rating to a “sell” rating in a research note on Tuesday.
View Our Latest Report on ATRI
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Recommended Stories
- Five stocks we like better than Atrion
- Where to Find Earnings Call Transcripts
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
- Most Volatile Stocks, What Investors Need to Know
- PDD Holdings Earnings Volatility Alerts Buyers
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.